The currently ongoing Phase Three clinical trial of the COVID-19 vaccine shows high protection rates against both symptomatic and severe cases six months after initial injection of the second dose, the company reported Thursday.
Protection is still considered by both virus experts and those at Pfizer to last longer than six months, but trials have not yet concluded that.
‘The vaccine was 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention (CDC), and 95.3% effective against severe COVID-19 as defined by the U.S. Food and Drug Administration (FDA),’ Pfizer and BioNTech said in a joint statement.
The vaccine also showed a 91 percent effectiveness rate against general symptomatic cases of the disease.
The companies also reported its effectiveness against the South African variant of the virus, along with sporting a 100% effectiveness rate in subjects between the ages of 12 and 15.